Integrated Multi-Omics Identifies Core Molecular Targets in Cerebral Venous Sinus Thrombosis-Induced Brain Injury

Xiaohong Qin1,2, Haoran Lu1,2, Zhibiao Chen1,2

  • 1Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Biomedicines
|July 28, 2026
PubMed

Insights

This study reveals key molecular targets and pathways in cerebral venous sinus thrombosis (CVST) brain injury using multi-omics. Glucocorticoids show potential therapeutic binding to identified targets like JAK2 and CD44.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Bioinformatics

Background:

  • Cerebral venous sinus thrombosis (CVST) causes significant brain injury and intracranial hypertension.
  • The molecular mechanisms underlying CVST remain poorly understood, hindering targeted therapy development.
  • This study addresses the need for comprehensive molecular insights into CVST-induced brain lesions.

Purpose of the Study:

  • To systematically identify key molecular targets and signaling pathways in CVST-induced brain injury.
  • To utilize multi-omics approaches for a detailed molecular landscape analysis.
  • To explore potential therapeutic targets and compounds for CVST treatment.

Main Methods:

  • Established an optimized rat model of cerebral venous sinus thrombosis (CVST).
  • Employed transcriptomic, proteomic, and single-cell RNA sequencing on cortical tissues.
  • Conducted comprehensive bioinformatics analyses, including network construction, molecular docking, and molecular dynamics simulations.

Main Results:

  • Identified 12 core genes (e.g., CD44, JAK2, CASP3) and associated pathways in immune response and tissue repair.
  • Single-cell sequencing confirmed gene expression and cell-type specificity.
  • Molecular docking suggested glucocorticoids (dexamethasone, methylprednisolone) bind effectively to JAK2, PTGS2, and CD44; methylprednisolone showed stable complex formation with CD44.

Conclusions:

  • Integrated multi-omics profiling provides a systematic molecular map of CVST-induced brain injury.
  • Identified novel candidate targets and signaling pathways offer a basis for further research.
  • Potential therapeutic compounds, including glucocorticoids, warrant further investigation for CVST treatment.